Viridian Therapeutics Correlations
| VRDN Stock | USD 12.19 0.08 0.66% |
The correlation of Viridian Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Viridian Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Viridian Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Modest diversification
The correlation between Viridian Therapeutics and NYA is 0.26 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Viridian Therapeutics and NYA in the same portfolio, assuming nothing else is changed.
Viridian |
The ability to find closely correlated positions to Viridian Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Viridian Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Viridian Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Viridian Therapeutics to buy it.
Moving together with Viridian Stock
| 0.87 | DVAX | Dynavax Technologies | PairCorr |
| 0.9 | EGRX | Eagle Pharmaceuticals | PairCorr |
| 0.83 | BMY | Bristol Myers Squibb | PairCorr |
| 0.8 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
| 0.85 | GILD | Gilead Sciences | PairCorr |
| 0.69 | IRWD | Ironwood Pharmaceuticals | PairCorr |
| 0.86 | ABBV | AbbVie Inc | PairCorr |
| 0.9 | ALKS | Alkermes Plc | PairCorr |
| 0.65 | AMPH | Amphastar P | PairCorr |
Moving against Viridian Stock
| 0.82 | BSGM | Biosig Technologies | PairCorr |
| 0.57 | MRK | Merck Company Financial Report 6th of August 2024 | PairCorr |
| 0.56 | AMRX | Amneal Pharmaceuticals Buyout Trend | PairCorr |
| 0.55 | DCPH | Deciphera Pharmaceuticals | PairCorr |
| 0.44 | AMGN | Amgen Inc | PairCorr |
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Viridian Stock performing well and Viridian Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Viridian Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| RNAZ | 7.40 | 2.33 | 0.19 | 0.65 | 9.76 | 28.78 | 99.24 | |||
| MLGO | 26.37 | 11.02 | 1.69 | 1.43 | 4.77 | 11.64 | 852.61 | |||
| MSTSX | 0.47 | 0.01 | 0.01 | 0.04 | 0.66 | 0.90 | 3.08 | |||
| RRTLX | 0.26 | 0.03 | 0.01 | 0.29 | 0.22 | 0.59 | 1.36 | |||
| ANTMX | 0.62 | 0.07 | 0.09 | 0.08 | 0.57 | 1.23 | 3.55 | |||
| MLGF | 0.37 | 0.01 | (0.02) | 0.10 | 0.46 | 1.11 | 2.94 | |||
| GSFI | 2.98 | 1.44 | 0.00 | 0.58 | 0.00 | 0.00 | 100.00 | |||
| COLD | 1.18 | (0.01) | 0.00 | 0.02 | 1.29 | 2.54 | 7.05 | |||
| SEIC | 0.62 | (0.04) | 0.00 | (0.01) | 0.00 | 1.34 | 4.74 |
Be your own money manager
Our tools can tell you how much better you can do entering a position in Viridian Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Analyst Advice Now
Analyst AdviceAnalyst recommendations and target price estimates broken down by several categories |
| All Next | Launch Module |
Viridian Therapeutics Corporate Management
Elected by the shareholders, the Viridian Therapeutics' board of directors comprises two types of representatives: Viridian Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Viridian. The board's role is to monitor Viridian Therapeutics' management team and ensure that shareholders' interests are well served. Viridian Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Viridian Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Seth Harmon | Principal Accounting | Profile | |
| Anthony Casicano | Chief Officer | Profile | |
| Kristian MBA | Chief CFO | Profile | |
| Anthony Casciano | Chief Officer | Profile | |
| Jennifer JD | Chief Officer | Profile | |
| Eric Olson | CoFounder Board | Profile |
Already Invested in Viridian Therapeutics?
The danger of trading Viridian Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Viridian Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Viridian Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Viridian Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Viridian Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Viridian Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Viridian Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Viridian Therapeutics Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viridian Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.Note that the Viridian Therapeutics information on this page should be used as a complementary analysis to other Viridian Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Complementary Tools for Viridian Stock analysis
When running Viridian Therapeutics' price analysis, check to measure Viridian Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viridian Therapeutics is operating at the current time. Most of Viridian Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viridian Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viridian Therapeutics' price. Additionally, you may evaluate how the addition of Viridian Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
Is Viridian Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viridian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.49) | Revenue Per Share 0.006 | Quarterly Revenue Growth (0.27) | Return On Assets (0.29) | Return On Equity (0.47) |
The market value of Viridian Therapeutics is measured differently than its book value, which is the value of Viridian that is recorded on the company's balance sheet. Investors also form their own opinion of Viridian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viridian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viridian Therapeutics' market value can be influenced by many factors that don't directly affect Viridian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Viridian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viridian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.